BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2026 8:53:15 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-02-02 02:22 |
|
Peer-Review Started |
|
2026-02-02 02:23 |
|
First Decision by Editorial Office Director |
|
2026-02-12 08:21 |
|
Return for Revision |
|
2026-02-12 08:21 |
|
Revised |
|
2026-03-06 15:30 |
|
Publication Fee Transferred |
|
2026-03-08 11:16 |
|
Second Decision by Editor |
|
2026-04-01 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-01 06:31 |
|
Articles in Press |
|
2026-04-01 06:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-05-11 01:40 |
|
Publish the Manuscript Online |
|
2026-05-20 08:53 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chun-Yan Zhou, Xin-Yi Ren, Huan-Huan Li, Xiao-Mei Pan, Xin Lan and Dong Duan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Natural Science Foundation of Chongqing, China |
CSTB2023NSCQ-MSX0678 |
|
| Corresponding Author |
Dong Duan, Department of Nuclear Medicine, Chongqing General Hospital, 118 Xingguang Avenue, Liangjiang New Area, Chongqing 400700, China. duandong26@163.com |
| Key Words |
Radioiodine-refractory differentiated thyroid cancer; Anlotinib; Albumin-bound paclitaxel; Combination therapy; Maintenance therapy; Case report |
| Core Tip |
Effective salvage treatments for radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) following sorafenib failure remain severely limited. This case report presents an innovative combination and maintenance strategy. By employing anlotinib plus albumin-bound paclitaxel as induction therapy to potentially promote vascular normalization and enhance cytotoxic drug delivery, followed by anlotinib maintenance, a patient with metastatic RAIR-DTC achieved a confirmed partial response. With manageable toxicity and progression-free survival exceeding 38 months, this case suggests that the anlotinib-based regimen may provide durable disease control and warrants further prospective evaluation in patients who have exhausted first-line multikinase inhibitors. |
| Publish Date |
2026-05-20 08:53 |
| Citation |
Zhou CY, Ren XY, Li HH, Pan XM, Lan X, Duan D. Anlotinib plus albumin-bound paclitaxel induction-maintenance for sorafenib-refractory radioiodine-refractory differentiated thyroid cancer: A case report and review of literature. World J Clin Oncol 2026; 17(5): 119615 |
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i5/119615.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v17.i5.119615 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
